{"id":194442,"date":"2025-12-16T09:25:07","date_gmt":"2025-12-16T09:25:07","guid":{"rendered":"https:\/\/www.newsbeep.com\/ie\/194442\/"},"modified":"2025-12-16T09:25:07","modified_gmt":"2025-12-16T09:25:07","slug":"noom-launches-longevity-focused-glp-1-program","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/ie\/194442\/","title":{"rendered":"Noom launches longevity-focused GLP-1 program"},"content":{"rendered":"

Preventive health offering combines \u2018microdosed\u2019 GLP-1 meds with biomarker monitoring and behavior change guidance. <\/p>\n

Digital health platform Noom<\/a> is broadening its business beyond weight management with today\u2019s launch of a preventive health and longevity program that combines microdoses of GLP-1 medication with behavior change and biomarker monitoring. The new program reflects the company\u2019s strategic shift toward addressing metabolic and cardiovascular risk earlier, targeting people who may not meet traditional criteria for obesity treatment but show biological signs associated with future disease.<\/p>\n

\u201cThe problem we\u2019re solving is that most Americans are living with suboptimal health \u2013 and their blood biomarkers show it,\u201d said Noom CMO Dr Jeffrey Egler. \u201cThat eventually manifests as chronic disease. In the United States today, roughly three in four adults in midlife are living with at least one chronic health condition.\u201d<\/p>\n

The latest Noom program combines three main elements: personalized, low-dose GLP-1 prescriptions; regular at-home blood testing; and ongoing digital behavior-change support delivered through the company\u2019s app. The goal is to help users understand and improve biomarkers linked to their cardiometabolic health, inflammation, and aging before chronic conditions develop.<\/p>\n

\"\" <\/p>\n

While most GLP-1 programs are focused primarily on weight loss and intended for clinically obese people, eligibility Noom\u2019s new offering begins at a body mass index of 21 or higher, which encompasses most US adults. Starting doses are set at roughly a quarter of the lowest starting dose used in Noom\u2019s other GLP-1 programs. The company cites third-party research and its own data indicating that the new dosage levels can influence metabolic biomarkers such as HbA1c, which has been linked to cardiovascular disease, cognitive aging, liver fat accumulation, kidney function, inflammation, fertility outcomes and mortality.<\/p>\n

\u201cToday marks the start of a new era for Noom,\u201d said Noom CEO Geoff Cook, highlighting presentations made at the recent AARD conference in Copenhagen where GLP-1s were described as longevity drugs<\/a>. \u201cNow, we can intervene sooner. We can get in front of chronic disease and reach people before metabolic disorder takes root.\u201d<\/p>\n

A central component of Noom\u2019s program is routine biomarker monitoring. Members receive an at-home blood testing kit every four months. The test panel includes 17 markers covering metabolic, cardiovascular, hormonal, inflammatory and nutritional domains. By repeating testing several times a year, Noom aims to help users see how medication use and daily habits affect their internal health over relatively short intervals.<\/p>\n

\"\" <\/p>\n

The digital longevity companion within the Noom app emphasizes daily microhabits related to nutrition, physical activity, stress management, and self-monitoring. The platform incorporates cognitive behavioral therapy techniques, alongside features such as AI-assisted food logging, body composition scanning and goal tracking.<\/p>\n

\u201cBy pairing healthy habits with microdosed medication, we aim to help members both understand and improve their biomarkers \u2013 and their long-term health \u2013 before disease develops,\u201d said Egler.<\/p>\n

Noom argues that the behavior change component is particularly important given high discontinuation rates for GLP-1 medications across the market and claims it is attempting to create durability beyond the period of pharmacologic support.<\/p>\n

\u201cGLP-1s can lower food noise and may boost self-efficacy for health,\u201d said Cook. \u201cAction produces results, results fuel motivation, and motivation transforms identity. Health becomes habit, not effort. When identity begins to shift, the door opens to broader transformation. The question becomes \u2018What else can I improve?\u2019\u201d<\/p>\n

Noom\u2019s new program is called Proactive Health Microdose GLP-1Rx and is priced at $149 per month.<\/p>\n

\u201cThe old healthcare model waited for disease and treated symptoms,\u201d said Egler. \u201cThe new era is proactive \u2013 integrating biology, psychology, and technology to prevent disease before it starts. GLP-1s are not a shortcut \u2013 they\u2019re the spark. They open the door for change, but actively walking through that door is what makes the transformation last.\u201d<\/p>\n

Photographs courtesy of Noom. <\/p>\n","protected":false},"excerpt":{"rendered":"Preventive health offering combines \u2018microdosed\u2019 GLP-1 meds with biomarker monitoring and behavior change guidance. Digital health platform Noom…\n","protected":false},"author":2,"featured_media":194443,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[34],"tags":[12015,2995,4368,103,397,396,55901,61,60,4591,29830,43,58879,16017,86865,103926,2114],"class_list":{"0":"post-194442","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-healthcare","8":"tag-biomarkers","9":"tag-blood-test","10":"tag-glp-1","11":"tag-health","12":"tag-health-care","13":"tag-healthcare","14":"tag-healthspan","15":"tag-ie","16":"tag-ireland","17":"tag-longevity","18":"tag-microdosing","19":"tag-news","20":"tag-noom","21":"tag-prevention","22":"tag-preventive-health","23":"tag-test-kits","24":"tag-weight-loss"},"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/posts\/194442","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/comments?post=194442"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/posts\/194442\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/media\/194443"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/media?parent=194442"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/categories?post=194442"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/tags?post=194442"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}